GMP

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, February 17, 2024

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).
  • IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe.
  • We are working hard to obtain interim results in 2024.
  • With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma.

AgriFORCE Granted Further Patent from the USPTO Related to its FORCEGH+ Facilities

Retrieved on: 
Friday, February 16, 2024

VANCOUVER, British Columbia, Feb. 16, 2024 (GLOBE NEWSWIRE) -- AgriFORCE Growing Systems Ltd. (“the Company”) (NASDAQ: AGRI; AGRIW), an intellectual property (IP) focused AgTech company, today announced that on February 13, 2024, the USPTO granted Patent No.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 16, 2024 (GLOBE NEWSWIRE) -- AgriFORCE Growing Systems Ltd. (“the Company”) (NASDAQ: AGRI; AGRIW), an intellectual property (IP) focused AgTech company, today announced that on February 13, 2024, the USPTO granted Patent No.
  • This continuation patent covers the innovative FORCEGH+ facility design, including its ability to integrate with different automated systems.
  • This patent expands on the Company’s previously announced patent related to its FORCEGH+ facilities.
  • FORCEGH+ facilities are designed as advanced AgTech, high efficiency building envelopes developed through proprietary engineering and materials.

Azzur Group Expands Service Portfolio with Analytical Services for Advanced Therapeutics, enhancing the Azzur Discovery to Delivery Platform

Retrieved on: 
Thursday, February 15, 2024

To enable this innovation and transformation of therapeutic options, Azzur Group today announces the introduction of analytical laboratory testing services for advanced therapeutic medicinal products (ATMPs).

Key Points: 
  • To enable this innovation and transformation of therapeutic options, Azzur Group today announces the introduction of analytical laboratory testing services for advanced therapeutic medicinal products (ATMPs).
  • The capabilities and expertise are built upon a foundation of safety, quality, and product stability to meet stringent regulatory requirements.
  • Azzur Group's ATMP Analytical Services include assay and protocol development (compendial and non-compendial), study design and execution, and analytical/bioanalytical testing.
  • "The comprehensive Azzur approach to advanced therapeutics offers clients a model of speed and adaptability that will revolutionize manufacturing flexibility in the industry."

Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing

Retrieved on: 
Thursday, February 15, 2024

The new building is currently being transformed into a state-of-the-art manufacturing facility.

Key Points: 
  • The new building is currently being transformed into a state-of-the-art manufacturing facility.
  • The state-of-the-art facility is to be equipped with the latest modern utilities and amenities, and will house dedicated areas for R&D, equipment production, formulation services, and product manufacturing.
  • Ken Micciche, PBIO’s Director of Business Development, commented: “We are very excited about the opportunities this consolidation and expansion presents.
  • This will enable PBIO to expand production capacity in UltraShear equipment installations, while maintaining stringent quality control and ensuring the total reliability of its products.

INCOG BioPharma Services adds 100 million units of syringe/cartridge capacity

Retrieved on: 
Thursday, February 15, 2024

FISHERS, Ind., Feb. 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.

Key Points: 
  • FISHERS, Ind., Feb. 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.
  • It will complement the company's existing multi-use filling line, bringing the company's total filling capacity to 140 million units per year.
  • In addition to the new filling line, INCOG recently added automated visual inspection capabilities and will soon complete qualification of equipment to support auto-injector device assembly services.
  • The decision to increase capacity, well before current capacity limits were reached, was based on a business philosophy that prioritizes customer needs.

CYTENA Launches The 2nd Generation UP.SIGHT And C.STUDIO - An All-in-one Solution for Industrial Cell Line Development Revolutionizing the Manufacturing of Biologics

Retrieved on: 
Thursday, February 15, 2024

FREIBURG, Germany, Feb. 15, 2024 /PRNewswire-PRWeb/ -- CYTENA GmbH, a BICO company and a global leader in single cell dispensing technologies, is pleased to announce the launch of the 2nd generation UP.SIGHT - a transformative single-cell dispenser and imager ushering in a new era in stable cell line development workflows.

Key Points: 
  • CYTENA GmbH, a subsidiary of BICO and a leading figure in single cell dispensing technologies, has recently unveiled the 2nd generation UP.SIGHT.
  • The system also introduces the C.STUDIO software, a sophisticated platform for data analysis and reporting tailored to cell line development.
  • CYTENA is also introducing an advanced CLD (Cell Line Development) analysis suite called C.STUDIO, alongside the new generation of UP.SIGHT.
  • It also features comprehensive reporting tools for regulatory submissions, making it the most sophisticated software designed specifically for enhancing cell line development workflows.

Mikart, LLC Expands Oral Solid Dose Manufacturing Capabilities

Retrieved on: 
Thursday, February 15, 2024

This strategic investment reaffirms Mikart's commitment to delivering high-quality pharmaceutical manufacturing services while staying at the forefront of technological advancements in the industry.

Key Points: 
  • This strategic investment reaffirms Mikart's commitment to delivering high-quality pharmaceutical manufacturing services while staying at the forefront of technological advancements in the industry.
  • "We are thrilled to expand our Fette® tablet press platforms into our manufacturing operations," said Michael Kallelis, CEO of Mikart, LLC.
  • "These high-speed and high-volume presses mark a significant milestone in our journey towards enhancing client satisfaction and accommodating the growing brand and generic market."
  • This recent expansion complements Mikart's existing portfolio of pilot-scale and commercial-scale equipment to serve our customers from early to late-phase development and manufacturing.

Enable Injections Announces Plans to Expand Manufacturing Facilities and Corporate Headquarters

Retrieved on: 
Wednesday, February 14, 2024

CINCINNATI, Feb. 14, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable technology, today announced it plans to expand manufacturing operations with a new large-scale facility in Springdale, Ohio as well as enhance the Company's corporate headquarters in Evendale, Ohio.  

Key Points: 
  • New state-of-the-art facility to be located in Springdale, Ohio
    CINCINNATI, Feb. 14, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable technology, today announced it plans to expand manufacturing operations with a new large-scale facility in Springdale, Ohio as well as enhance the Company's corporate headquarters in Evendale, Ohio.
  • New state-of-the-art facility will support ongoing clinical and commercial supply of Enable Injections’ enFuse technology.
  • The Company's new 90,000 square-foot Manufacturing Center of Excellence will support ongoing in-house manufacturing and supply of the Company's enFuse medicine delivery technology.
  • In addition to the new Manufacturing Center of Excellence in Springdale, Enable will be renovating and enhancing the infrastructure of its Evendale headquarters.

Enable Injections Announces Plans to Expand Manufacturing Facilities and Corporate Headquarters

Retrieved on: 
Wednesday, February 14, 2024

CINCINNATI, Feb. 14, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable technology, today announced it plans to expand manufacturing operations with a new large-scale facility in Springdale, Ohio as well as enhance the Company's corporate headquarters in Evendale, Ohio.  

Key Points: 
  • New state-of-the-art facility to be located in Springdale, Ohio
    CINCINNATI, Feb. 14, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable technology, today announced it plans to expand manufacturing operations with a new large-scale facility in Springdale, Ohio as well as enhance the Company's corporate headquarters in Evendale, Ohio.
  • The Company's new 90,000 square-foot Manufacturing Center of Excellence will support ongoing in-house manufacturing and supply of the Company's enFuse medicine delivery technology.
  • In addition to the new Manufacturing Center of Excellence in Springdale, Enable will be renovating and enhancing the infrastructure of its Evendale headquarters.
  • The Company's headquarters presently houses GMP-compliant manufacturing space to support current clinical and commercial demand of enFuse, as well as labs and administrative areas.

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Retrieved on: 
Tuesday, February 13, 2024

REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a loan facility agreement with an affiliate of Innovatus Capital Partners, LLC (Innovatus) for up to $40 million, including $30 million upfront and access to an additional $10 million upon achieving certain prespecified revenue thresholds. This loan facility reinforces the strength of Codexis’ cash position, provides additional flexibility to its projected runway through cash-flow positive around the end of 2026 and will support the ongoing development and commercialization of the Company’s Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform.

Key Points: 
  • After a competitive process, we are excited to partner with a leading financier like Innovatus, who truly understand the incredible opportunity that RNAi therapeutics represents,” said Stephen Dilly, MBBS, PhD, Chief Executive Officer of Codexis.
  • The loan carries an interest-only period of 36 months and a total term of 60 months.
  • A live webcast to accompany the conference call will be available on the Investors section of the Company website at www.codexis.com/investors .
  • A webcast replay will be available on the Investors section of the Company website for 30 days, beginning approximately two hours after the completion of the call.